APPENDIX
Details of the Procedure
Validation of referred partners. We took several steps to minimize the possibility that reported partnerships involving successfully referred partners were fabricated. First, for index individuals who indicated they could locate >5 partners, only 5 were randomly selected for referral. Therefore, such index individuals could not plan in advance who their fabricated partners would be. Second, we collected detailed physical/identifying information from index individuals on the partners whom they were to refer. We compared this information with the persons presenting as index individuals' partners, and we rejected those whose physical/identifying information did not match that reported by the index individual (this occurred infrequently). Third, we asked referred partners how they got their vouchers and information about the persons who referred them. If persons presenting as partners either reported not knowing the index previously or reported information inconsistent with the description of the index, they were rejected.
Laboratory
procedures. Oligonucleotide
primers used in the first round of PCR
amplification were 5-GCGTCCGGGTTCTGGAAGACGGCGTGAACTATGCAACAGG-3
(corresponding to nucleotides 802–841
of the HCV1 genome) and 5
-AGGCTTTCATTGCAGTTCAAGGCCGTGCTATTGATGTGCC-3
(corresponding to nucleotides
1600–1639 of the HCV1 genome). The 805-bp
product of the second round of PCR was
generated using primers 5
-AAGACGGCGTGAACTATGCAACAGGGAACCTTCCTGGTTG-3
(corresponding to nucleotides 821–856
of the HCV1 genome) and 5
-AGTTCAAGGCCGTGCTATTGATGTGCCAACTGCCGTTGGT-3
(corresponding to nucleotides
1626–1587 of the HCV1 genome). PCR products
were purified by agarose-gel electrophoresis with the Qiaex
gel-purification kit (Qiagen). The purified PCR products
were directly sequenced using the second-round-PCR
primers.